Cited by 113SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Prophylaxis against covid-19: living systematic review and network meta-analysis

Open access

Bartoszko, Jessica J, Siemieniuk, Reed AC, Kum, Elena, Qasim, Anila, Zeraatkar, Dena, Martinez, Juan Pablo Diaz, Azab, Maria, Ibrahim, Sara, Izcovich, Ariel, Soto, Gonzalo Bravo, Roldan, Yetiani, Agarwal, Arnav, Agoritsas, Thomas, Chu, Derek K, Couban, Rachel, Devji, Tahira, Foroutan, Farid, Ghadimi, Maryam, Honarmand, Kimia, Khamis, Assem, Lamontagne, Francois, Loeb, Mark, McLeod, Shelley L, Motaghi, Sharhzad, Murthy, Srinivas, Mustafa, Reem A, Rochwerg, Bram, Switzer, Charlotte, Thabane, Lehana, Vandvik, Per O, Vernooij, Robin WM, Wang, Ying, Yao, Liang, Guyatt, Gordon H, Brignardello-Petersen, Romina·2021·BMJ

DOI 10.1136/bmj.n949PMC PMC8073806

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Updates: This is the second version (first update) of the living systematic review, replacing the previous version (available as a data supplement). When citing this paper please consider adding the version number and date of access for clarity. Objective: To determine and compare the effects of drug prophylaxis on severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (covid-19). Design: Living systematic review and network meta-analysis (NMA). Data sources: WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature to 4 March 2022. Study selection: Randomised trials in which people at risk of covid-19 were allocated to prophylaxis or no prophylaxis (standard care or placebo). Pairs of reviewers independently screened potentially eligible articles. Methods: After duplicate data abstraction, we conducted random-effects bayesian network meta-analysis. We assessed risk of bias of the included studies using a modification of the Cochrane risk of bias 2.0 tool and assessed the certainty of the evidence using the grading of recommendations assessment, development and evaluation (GRADE) approach. Results: The second iteration of this living NMA includes 32 randomised trials which enrolled 25 147 participants and addressed 21 different prophylactic drugs; adding 21 trials (66%), 18 162 participants (75%) and 16 (76%) prophylactic drugs. Of the 16 prophylactic drugs analysed, none provided convincing evidence of a reduction in the risk of laboratory confirmed SARS-CoV-2 infection. For admission to hospital and mortality outcomes, no prophylactic drug proved different than standard care or placebo. Hydroxychloroquine and vitamin C combined with zinc probably increase the risk of adverse effects leading to drug discontinuation—risk difference for hydroxychloroquine (RD) 6 more per 1000 (95% credible interval (CrI) 2 more to 10 more); for vitamin C combined with zinc, RD 69 more per 1000 (47 more to 90 more), moderate certainty evidence. Conclusion: Much of the evidence remains very low certainty and we therefore anticipate future studies evaluating drugs for prophylaxis may change the results for SARS-CoV-2 infection, admission to hospital and mortality outcomes. Both hydroxychloroquine and vitamin C combined with zinc probably increase adverse effects. Systematic review registration: This review was not registered. The protocol established a priori is included as a supplement. Funding: This study was supported by the Canadian Institutes of Health Research (grant CIHR-IRSC:0579001321).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.n949

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

3 retracted

WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 PandemicPreprint
Elgazzar, A. G., Hani, B. M., Youssef, S. A., Hafez, M., Moussa, H. H., & El-Taweel, A. I. (2020) · Research Square · doi:10.21203/rs.3.rs-100956/v2 · Cited by 24
Retracted
WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Elgazzar, A., Eltaweel, A., Youssef, S. A., Hany, B., Hafez, M., & Moussa, H. (2020) · doi:10.21203/rs.3.rs-100956/v3 · Cited by 17
Retracted
RETRACTED: Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial.
Balmforth, D., Swales, J. A., Silpa, L., Dunton, A. W., Davies, K. E., Davies, S. G., Kamath, A., Gupta, J., Gupta, S., Masood, M. A., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105248 · Cited by 14
Retracted
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Self-citation
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
Puhan, M. A., Schunemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., Kessels, A. G., Guyatt, G. H., & for the GRADE Working Group (2014) · BMJ · doi:10.1136/bmj.g5630 · Cited by 1,812
Self-citation
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,349
A living WHO guideline on drugs for covid-19 (2020-2023)
Agarwal, A., Hunt, B. J., Stegemann, M., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L., Leo, Y.-S., et al. (2020) · BMJ · doi:10.1136/bmj.m3379 · Cited by 1,041
Self-citation

Flagged first, then by citations

Show all 84 references

Research works printed but not linked: 10

10.1016/j.jclinepi.2017.08.010 · DOI · Paper page
Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia.
10.1371/journal.pone.0076654 · DOI · Paper page
10.1056/NEJMoa2016638 · DOI
10.1056/NEJMoa2021801 · DOI
10.7860/JCDR/2020/46795.0000 · DOI
10.1016/j.jacc.2020.05.040 · DOI
10.1371/journal.pone.0244778 · DOI
10.18433/jpps31457 · DOI
10.1016/j.jclinepi.2010.07.017 · DOI · Paper page

Sorted by citations

Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Self-citation
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., Wang, L., Griffiths, C., Brown, M. L., Scott, W. E., et al. (2022) · Nature · doi:10.1038/s41586-022-05594-0 · Cited by 299
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Drożdżal, S., Rosik, J., Lechowicz, K., Machaj, F., Szostak, B., Przybyciński, J., Lorzadeh, S., Kotfis, K., Ghavami, S., & Łoś, M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100794 · Cited by 301
A guide and pragmatic considerations for applying GRADE to network meta-analysis
Izcovich, A., Chu, D. K., Mustafa, R. A., Guyatt, G. H., & Brignardello‐Petersen, R. (2023) · BMJ · doi:10.1136/bmj-2022-074495 · Cited by 194
Self-citation
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Chu, A. W. L., Wong, M. M., Rayner, D. G., Guyatt, G. H., Martinez, J. P. D., Ceccacci, R., Zhao, I. X., McMullen, E. P., Srivastava, A., Wang, J., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.029 · Cited by 179
Self-citation
A living WHO guideline on drugs to prevent covid-19
Lamontagne, F., Stegemann, M. S., Agarwal, A., Agoritsas, T., Siemieniuk, R. A. C., Rochwerg, B. N., Bartoszko, J. J., Askie, L. M., Macdonald, H., AlMaslamani, M. A. R. S., et al. (2021) · BMJ · doi:10.1136/bmj.n526 · Cited by 135
Self-citation
Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Chu, D. K., Chu, A. W. L., Rayner, D. G., Guyatt, G. H., Yepes-Núñez, J. J., Gómez-Escobar, L. G., Pérez-Herrera, L. C., Martinez, J. P. D., Brignardello‐Petersen, R., Sadeghirad, B., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.030 · Cited by 128
Self-citation
Self-medication practices to prevent or manage COVID-19: A systematic review
Quincho-Lopez, A., Benites-Ibarra, C. A., Hilario-Gómez, M. M., Quijano-Escate, R., & Taype-Rondán, Á. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259317 · Cited by 116
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Díaz Martinez, J. P., Kum, E., Qasim, A., Zeraatkar, D., Izcovich, A., Mangala, S., Ge, L., Han, M. A., et al. (2021) · BMJ · doi:10.1136/bmj.n2231 · Cited by 79
Self-citation
An update of anti-viral treatment of COVID-19
Yavuz, S. Ş., & Celikyurt, I. K. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2106-250 · Cited by 88
Translating Evidence to Optimize Patient Care Using GRADE
Chu, D. K., Golden, D. B. K., & Guyatt, G. H. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.09.035 · Cited by 79
Self-citation
Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation
Akl, E. A., Khabsa, J., Iannizzi, C., Piechotta, V., Kahale, L. A., Barker, J. M., McKenzie, J. E., Page, M. J., & Skoetz, N. (2024) · BMJ · doi:10.1136/bmj-2024-079183 · Cited by 103
“43”
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
Martins‐Filho, P. R., Ferreira, L. C., Heimfarth, L., Araújo, A. A. D. S., & Quintans‐Júnior, L. J. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100062 · Cited by 61
Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets
Yapasert, R., Khaw-on, P., & Banjerdpongchai, R. (2021) · Molecules · doi:10.3390/molecules26247459 · Cited by 55
The scenario of self-medication practices during the covid-19 pandemic; a systematic review
Shrestha, A. B., Aryal, M., Magar, J. R., Shrestha, S., Hossainy, L., & Rimti, F. H. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104482 · Cited by 61
Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review
Zeraatkar, D., Pitre, T., Leung, G., Cusano, E., Agarwal, A., Khalid, F., Escamilla, Z., Cooper, M. A., Ghadimi, M., Wang, Y., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000309 · Cited by 44
Self-citation
Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19
García‐Albéniz, X., del Amo, J., Polo, R., Morales‐Asencio, J. M., & Hernán, M. Á. (2022) · European Journal of Epidemiology · doi:10.1007/s10654-022-00891-4 · Cited by 38
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
Cadegiani, F., Goren, A., Wambier, C. G., & McCoy, J. M. (2021) · New Microbes and New Infections · doi:10.1016/j.nmni.2021.100915 · Cited by 38
Review of the WHO guideline on preventive chemotherapy for public health control of strongyloidiasis
Lo, N. C., Addiss, D. G., Buonfrate, D., Amor, A., Anegagrie, M., Bisoffi, Z., Bradbury, R. S., Keiser, J., Kepha, S., Khieu, V., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00595-4 · Cited by 40
Self-citation
Triangle of cytokine storm, central nervous system involvement, and viral infection in COVID-19: the role of sFasL and neuropilin-1
Saleki, K., Banazadeh, M., Miri, N. S., & Azadmehr, A. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0047 · Cited by 37
Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis
Cruciani, M., Pati, I., Masiello, F., Malena, M., Pupella, S., & Angelis, V. D. (2021) · Diagnostics · doi:10.3390/diagnostics11091645 · Cited by 34
Drug safety of frequently used drugs and substances for self-medication in COVID-19
Baracaldo-Santamaría, D., Pabón-Londoño, S., & Rojas-Rodríguez, L. C. (2022) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986221094141 · Cited by 33
The Effect of Circulating Zinc, Selenium, Copper and Vitamin K1 on COVID-19 Outcomes: A Mendelian Randomization Study
Sobczyk, M., & Gaunt, T. R. (2022) · Nutrients · doi:10.3390/nu14020233 · Cited by 31
Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis
Pitre, T., Su, J. S., Cui, S., Scanlan, R., Chiang, C., Husnudinov, R., Khalid, M. F., Khan, N., Leung, G., Mikhail, D., et al. (2022) · European Respiratory Review · doi:10.1183/16000617.0036-2022 · Cited by 32
Self-citation
Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare
Leung, E. H., Fan, J., Flynn, H. W., & Albini, T. A. (2022) · Clinical ophthalmology · doi:10.2147/opth.s336963 · Cited by 29
Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: Systematic review and network meta-analysis with meta-epsidemiological approach
Douillet, D., Chapelle, C., Ollier, É., Mismetti, P., Roy, P., & Laporte, S. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004059 · Cited by 31
Methodological quality and reporting quality of COVID-19 living systematic review: a cross-sectional study
Luo, J., Chen, Z., Liu, D., Li, H., He, S., Zeng, L., Yang, M., Liu, Z., Xiao, X., & Zhang, L. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-01980-y · Cited by 27
Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease
Li, Y., Zhu, N., Cui, X., Lin, Y., & Li, X. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1178590 · Cited by 25
Artificial intelligence in COVID-19 evidence syntheses was underutilized, but impactful: a methodological study
Tercero-Hidalgo, J. R., Khan, K. S., Bueno‐Cavanillas, A., López, R. F., Huete, J. F., Amezcua‐Prieto, C., Zamora, J., & Fernández-Luna, J. M. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.04.027 · Cited by 23
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
Cheng, Q., Chen, J., Jia, Q., Fang, Z., & Zhao, G. (2021) · Aging · doi:10.18632/aging.203522 · Cited by 23
Medical preparedness for bioterrorism and chemical warfare: A public health integration review
Ugwu, C. N., Ugwu, O. P.-C., Alum, E. U., Eze, V. H. U., Basajja, M., Ugwu, J. N., Ogenyi, F. C., Ejemot-Nwadiaro, R. I., Okon, M. B., Egba, S. I., et al. (2025) · Medicine · doi:10.1097/md.0000000000042289 · Cited by 23
Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis
Ibrahim, S., Siemieniuk, R. A. C., Oliveros, M. J., Islam, N., Martinez, J. P. D., Izcovich, A., Qasim, A., Zhao, Y., Zaror, C., Yao, L., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081165 · Cited by 20
Self-citation
Improving the adherence to COVID-19 preventive measures in the community: Evidence brief for policy
Fulone, I., Barreto, J. O. M., Barberato-Filho, S., Bergamaschi, C. D. C., & Lopes, L. C. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.894958 · Cited by 15
Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
Kawazoe, M., Kihara, M., & Nanki, T. (2021) · Pharmaceuticals · doi:10.3390/ph14121256 · Cited by 15
Comparison of effect estimates between preprints and peer-reviewed journal articles of COVID-19 trials
Davidson, M., Evrenoglou, T., Graña, C., Chaimani, A., & Boutron, I. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-023-02136-8 · Cited by 9
Contemporary narrative review of treatment options for COVID ‐19
Shang, L., Lye, D. C., & Cao, B. (2021) · Respirology · doi:10.1111/resp.14106 · Cited by 11
Ayurvedic formulations: Potential COVID-19 therapeutics?
Ali, A. A. M., Bugarc̀ić, A., Naumovski, N., & Ghildyal, R. (2022) · Phytomedicine Plus · doi:10.1016/j.phyplu.2022.100286 · Cited by 13
Mechanisms of gastrointestinal barrier dysfunction in COVID-19 patients
Xue, W., Honda, M., & Hibi, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i15.2283 · Cited by 12
Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis
Zhou, G., Verweij, S., Bijlsma, M. J., de Vos, S., Oude Rengerink, K., Pasmooij, A. M. G., van Baarle, D., Niesters, H. G. M., Mol, P., Vonk, J. M., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001674 · Cited by 11
Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial
Abarca, K., V, Iturriaga, C., Urzua, M. D., Corre, N. L., Pineda, A., Fernández, C., Domínguez, A., González, P. A., Bueno, S. M., Donato, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10071082 · Cited by 10
Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
Mohseni, M. M., Ameri, H., & Arab‐Zozani, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.966632 · Cited by 14
Ivermectin and the Integrity of Healthcare Evidence During COVID-19
O’Mathúna, D. P. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.788972 · Cited by 11
The Impact of Serum Levels of Vitamin D3 and Its Metabolites on the Prognosis and Disease Severity of COVID-19
Khojah, H. M. J., Ahmed, S., Althagfan, S. S., Alahmadi, Y. M., & Abdou, Y. A. (2022) · Nutrients · doi:10.3390/nu14245329 · Cited by 11
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Schilling, W. H., Callery, J. J., Chandna, A., Hamers, R. L., Watson, J. A., & White, N. J. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16741.1 · Cited by 10
Maoto, a traditional herbal medicine, for post-exposure prophylaxis for Japanese healthcare workers exposed to COVID-19: A single center study
Nabeshima, A., Sakamoto, A., Iwata, K., Kitamura, Y., Masui, S., Inomata, S., Iida, M., Iida, T., & Nabeshima, S. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.03.014 · Cited by 10
Impact of Allocation Concealment and Blinding in Trials Addressing Treatments for COVID-19: A Methods Study
Zeraatkar, D., Pitre, T., Díaz-Martínez, J. P., Chu, D. K., Rochwerg, B. N., Lamontagne, F., Kum, E., Qasim, A., Bartoszko, J. J., & Brignardello‐Petersen, R. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad131 · Cited by 11
Self-citation
Lessons from SARS‑CoV‑2 and its variants (Review)
Qin, Z., Sun, Y., Zhang, J., Zhou, L., Chen, Y., & Huang, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12779 · Cited by 10
No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study
Davidson, M., Evrenoglou, T., Graña, C., Chaimani, A., & Boutron, I. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.08.011 · Cited by 8
What do we know about covid in immunocompromised people?
Lang, K. (2023) · BMJ · doi:10.1136/bmj.p1612 · Cited by 9
Pharmacological interventions to prevent Covid‐19 disease: A rapid review
Cardwell, K., Murchú, É. Ó., Byrne, P., Broderick, N., Walsh, K. A., O’Neill, S. M., Smith, S. M., Harrington, P., Ryan, M., & O’Neill, M. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2299 · Cited by 9
Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia
Schaffer, A. L., Henry, D. A., Zoëga, H., Elliott, J., & Pearson, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269482 · Cited by 9
Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials
Battaglini, D., Robba, C., Pelosi, P. P., & Rocco, P. R. M. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2105833 · Cited by 9
Perceptions of COVID-19 symptoms, prevention, and treatment strategies among people in seven Arab countries: A cross-sectional study
Jirjees, F., Barakat, M. M., Shubbar, Q., Othman, B., Alzubaidi, H., & Al-Obaidi, H. J. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.019 · Cited by 12
A systematic survey of 200 systematic reviews with network meta-analysis (published 2020–2021) reveals that few reviews report structured evidence summaries
Løvsletten, P. O., Wang, X., Pitre, T., Ødegaard, M., Veroniki, A. A., Lunny, C., Tricco, A. C., Agoritsas, T., & Vandvik, P. O. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111445 · Cited by 7
Self-citation
What we learned in the past year in managing our COVID-19 patients in intensive care units?
Jain, N., Kashyap, R., & Surani, S. (2021) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v10.i4.81 · Cited by 8
Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic
Kountouras, J., Gialamprinou, D., Kotronis, G., Papaefthymiou, A., Economidou, E. C., Soteriades, E. S., Vardaka, E., Chatzopoulos, D., Tzitiridou‐Chatzopoulou, M., Papazoglou, D. D., et al. (2022) · Medicina · doi:10.3390/medicina58020309 · Cited by 8
Characteristics of Living Systematic Review for COVID-19
Chen, Z., Luo, J., Li, S., Xu, P., Zeng, L., Yu, Q., & Zhang, L. (2022) · Clinical Epidemiology · doi:10.2147/clep.s367339 · Cited by 7
Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics
Battaglini, D., Cruz, F. F., Robba, C., Pelosi, P. P., & Rocco, P. R. M. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2120801 · Cited by 7
Long COVID in Patients with Rheumatologic Disease: A Single Center Observational Study
Quiñones-Moya, H., Valle, A. O.-D., Camargo‐Coronel, A., Jiménez-Balderas, F. J., Bernal-Enriquez, M. B., Rodríguez, P. M., Morales-Medino, K. N., Roque-Ibañez, C., & Hernández-Zavala, M. R. (2022) · Indian Journal of Rheumatology · doi:10.4103/injr.injr_118_22 · Cited by 7
Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection
Ragó, Z., Tóth, B., Szalenkó-Tőkés, Á., Bella, Z., Dembrovszky, F., Farkas, N., Kiss, S., Hegyi, P., Matúz, M., Tóth, N., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00756-y · Cited by 7
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
Labhardt, N. D., Smit, M., Petignat, I., Perneger, T., Marinosci, A., Ustero, P., Ribeiro, M. P. D., Ragozzino, S., Nicoletti, G. J., Faré, P. B., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101188 · Cited by 8
Self-citation
COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
Moraes, R. R., Corrêa, M. B., Martins‐Filho, P. R., Lima, G. D. S., & Demarco, F. F. (2022) · Journal of Applied Oral Science · doi:10.1590/1678-7757-2022-0016 · Cited by 5
Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial
George, B., Moorthy, M., Kulkarni, U. P., Selvarajan, S., Rupali, P., Christopher, D. J., Thangakunam, B., Rose, W., Lakshmi, K. M., Devasia, A. J., et al. (2022) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-022-01546-w · Cited by 5
Physicians found an interactive tool displaying structured evidence summaries for multiple comparisons understandable and useful: a qualitative user testing study
Løvsletten, P. O., Hunskaar, B. S., Heen, A. F., Bekkering, G. E., Poel, L. V., Zeraatkar, D., Vermandere, M., Aertgeerts, B., Delvaux, N., Achille, F., et al. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111399 · Cited by 5
Self-citation
Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study
Kamstrup, P. T., Sivapalan, P., Eklöf, J. V., Hoyer, N., Ulrik, C. S., Pedersen, L., Lapperre, T. S., Harboe, Z. B., Bødtger, U. C. S., Bojesen, R. D., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.076 · Cited by 5
COVID-19 Treatments: Then and Now
Mustafa, S. S., Stern, R. A., Patel, P. C., & Chu, D. K. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.07.045 · Cited by 4
Self-citation
Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection
Stagnoli, S., Macari, G., Corsi, P., Capone, B., Vidaurrazaga, A., Ereño‐Orbea, J., Ardá, A., Polticelli, F., Jiménez‐Barbero, J., Abrescia, N. G. A., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c02921 · Cited by 4
Traditional, complementary and integrative medicine therapies for the treatment of mild/moderate acute COVID-19: protocol for a systematic review and network meta-analysis
Li, A., Guyatt, G. H., Chu, D. K., Thabane, L., Busse, J. W., Sadeghirad, B., He, Q., Ge, L., Hao, Q., Vohra, S., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088959 · Cited by 4
Self-citation
Safety profile of nivolumab-relatlimab in cancer patients: a living pharmacovigilance study of clinical trials and postmarketing data (version 1.0)
Zhu, J., Wu, Q., Yang, Z., Wu, C., Zhou, J., Li, S., Wu, J., & Jiang, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177991 · Cited by 3
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians
Haeussler, K., Ismaila, A., Malmenäs, M., Noorduyn, S. G., Green, N., Compton, C. H., Thabane, L., Vogelmeier, C. F., & Halpin, D. M. G. (2024) · Respiratory Research · doi:10.1186/s12931-024-03056-x · Cited by 4
Self-citation
Bromhexine, for Post Exposure COVID-19 Prophylaxis: A Randomized, Double-Blind, Placebo Control TrialPreprint
Tolouian, R., Moradi, O., Mulla, Z. D., Ziaie, S., Haghighi, M., Esmaily, H., Amini, H., Hassanpour, R., Pourheidar, E., Kouchek, M., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3989849 · Cited by 3
UDCA, a novel strategy for preventing SARS-CoV-2 infection via FXR-mediated ACE2 downregulation
Chen, M., Zhu, R., & Zhang, M. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023075 · Cited by 2
Bromhexine for Post-exposure COVID-19 Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial
Tolouian, R., Moradi, O., Mulla, Z. D., Ziaie, S., Haghighi, M., Esmaily, H., Amini, H., Hassanpour, R., Poorheidar, E., Kouchek, M., et al. (2022) · Jundishapur Journal of Microbiology · doi:10.5812/jjm-130198 · Cited by 2
Cutaneous Virus Infections
Sălăvăstru, C., Manole, I., Chiriac, A. E., & Ţiplica, G. (2021) · Springer eBooks · doi:10.1007/978-3-319-53805-1_68 · Cited by 2
A liver drug reduces SARS-CoV-2 entry into cells
(2022) · Nature · doi:10.1038/d41586-022-04149-7 · Cited by 2
Covid-19: India’s crisis is everyone’s crisis
Abbasi, K. A. (2021) · BMJ · doi:10.1136/bmj.n1152 · Cited by 1
Conduct and reporting of multivariate network meta-analyses: a scoping review
Bartoszko, J. J., García, M. G., Martinez, J. P. D., Yegorov, S., Brignardello‐Petersen, R., Mertz, D., Thabane, L., & Loeb, M. B. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.111238 · Cited by 2
Self-citation
The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis and clinical assessment: an updated meta-analysis of randomized trials
Han, X., Shi, W., & Yang, Y. P. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1043 · Cited by 1
Risk of bias and low reproducibility in meta-analytic evidence from fast-tracked publications during the coronavirus disease 2019 pandemic
Liu, X., Li, W., Zhang, Q., Lei, J., Han, X., Wang, Y., Shen, C., Yu, Z., Li, Y., Shi, L., et al. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf238 · Cited by 1
Self-citation
Clinical effects of ursodeoxycholic acid in COVID-19 infection: a systematic review and dose–response meta-analysis
Song, J. H., Shim, S. R., Shin, J., Choe, W. H., Park, J., Lee, T. H., Kang, S., Rhee, T. G., & Huh, K. C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1719144 · Cited by 2
Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study
Kim, B., Jung, J., Han, K., Kang, S., Lee, E., Chung, H., Kim, S. G., & Cho, S. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e99 · Cited by 1
Ivermectin
O’Malley, P. A. (2021) · Clinical Nurse Specialist · doi:10.1097/nur.0000000000000640 · Cited by 1
Non-immune Prophylaxis Against COVID-19 by Targeting Tolerance for Angiotensin II-Triggered SARS-CoV-2 Pathogenesis
Dubina, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.776903 · Cited by 1
ESTUDOS SOBRE MEDICAMENTOS PARA COVID-19: PARADIGMA DO ACESSO À INFORMAÇÃO E DA AUTOMEDICAÇÃO
Barroso, E. E. N., Geron, V. L. M. G., Vitorino, K. D. A., & Nunes, J. D. S. (2021) · Revista Científica FAEMA · doi:10.31072/rcf.v12i2.921 · Cited by 1
COVID-19 therapy: What works? What doesn’t? And what’s on the horizon?
Kulshreshtha (2022) · The Journal of Family Practice · doi:10.12788/jfp.0474 · Cited by 1
WHO COVID-19 therapeutic guidelines – Authors' reply
White, N. J., Wourgaft, N. S., Faiz, A., & Guerin, P. J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01327-1 · Cited by 1
Effects of allocation concealment and blinding in trials addressing treatments for COVID-19: A methods studyPreprint
Zeraatkar, D., Pitre, T., Díaz-Martínez, J. P., Chu, D. K., Rochwerg, B. N., Lamontagne, F., Kum, E., Qasim, A., Bartoszko, J. J., & Brignardello‐Petersen, R. (2022) · medRxiv · doi:10.1101/2022.08.03.22278348 · Cited by 1
Self-citation
An Innovative Modification of Grade's Minimally Contextualized Framework to Categorize Interventions in a Network Meta-AnalysisPreprint
Shi, Q., Guyatt, G. H., Hao, Q., & Li, S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4131124 · Cited by 1
Self-citation
Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria
García-Matarín, L., Velilla-Zancada, S., Trillo‐Calvo, E., Molina-Escribano, F., & Serrano-Cumplido, A. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.06.009
Extreme immunotherapy: emergency immunology to defeat pandemics
Nixon, D. F., Marín‐Hernández, D., & Hupert, N. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00366-4
Prevention of Venous Thromboembolic Events in Patients with Lower Leg Immobilization after Trauma: Systematic Review and Network Meta-Analysis with Meta-Epidemiological ApproachPreprint
Douillet, D., Chapelle, C., Ollier, É., Mismetti, P., Roy, P., & Laporte, S. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3973442
Perilaku Swamedikasi pada Pandemi COVID-19
Yadika, A. D. N. (2022) · Journal of Experimental and Clinical Pharmacy (JECP) · doi:10.52365/jecp.v2i1.372
Physical and Behavioral Health of Health Science Students of a Medical College of Nepal during COVID Pandemic
Mahotra, N. B., Kandel, S., Gurung, S., & Joshi, B. (2022) · Med Phoenix · doi:10.3126/medphoenix.v6i2.38165
Rural Medical Care and COVID-19
HAYAKAWA, S. (2022) · JOURNAL OF THE JAPANESE ASSOCIATION OF RURAL MEDICINE · doi:10.2185/jjrm.70.594
CURADORIA CIENTÍFICA DE DEPOIMENTO DE UMA MÉDICA À CPI DA COVID: CIÊNCIA OU IDEOLOGIA?*
Ferrari, C. K. B. (2022) · Cadernos do CEAS Revista crítica de humanidades · doi:10.25247/2447-861x.2021.n254.p531-547
PROPHYLACTIC USE OF ALLOPATHIC, COMPLEMENTARY & ALTERNATIVE MEDICINE (CAM) FOR COVID-19: A CROSS SECTIONAL SURVEY AMONG MEDICAL POST-GRADUATES OF TERTIARY CARE TEACHING HOSPITALS, GUJARAT
Patel, D. K., Piparva, K. G., & Singh, A. P. (2022) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/0400207
Model exploration for discovering COVID-19 targeted traditional Chinese medicine
Sun, Y., An, X., Jin, D., Duan, L., Zhang, Y., Yang, C., Duan, Y., Zhou, R., Zhao, Y., Zhang, Y., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12333
The Comparison of Clinical Epidemiology of Hospitalized Patients with COVID-19 during the Third and Fourth Waves of the Pandemic in Gorgan
Eshghinia, S., Sharififar, R. A., Hajimoradloo, N., Sinesepehr, A., Sohrsbi, A., Imeri, M., Kalti, A. R. K., Shirazi, E. R., & Golsha, R. (2022) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2022/9634241
Metabolites and metabolomics in COVID-19
Gowda, D., Kellarai, A., Hegde, P. S., Agni, M. B., Lundstrom, K. H., & Barh, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91794-0.00026-3
Oral Magnesium Supplements for Management of Pediatric Asthma Patients
Omar, S. F., Elkasrawy, M. M., Elmeazawy, R. Z., Soliman, G. A. E.-M., & El-Ezz, A. A. E.-B. A. (2023) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2023/v35i14930

Authors: Bartoszko, J. J., Siemieniuk, R. A., Kum, E., Qasim, A., Zeraatkar, D., Martinez, J. P. D., Azab, M., Ibrahim, S., Izcovich, A., Soto, G. B., Roldan, Y., Agarwal, A., Agoritsas, T., Chu, D. K., Couban, R., Devji, T., Foroutan, F., Ghadimi, M., Honarmand, K., Khamis, A., Lamontagne, F., Loeb, M., McLeod, S. L., Motaghi, S., Murthy, S., Mustafa, R. A., Rochwerg, B., Switzer, C., Thabane, L., Vandvik, P. O., Vernooij, R. W., Wang, Y., Yao, L., Guyatt, G. H., & Brignardello-Petersen, R.
Affiliations: McMaster University (CA)
Hospital Alemán (AR)
University of Toronto (CA)
University Hospital of Geneva (CH)
Western University (CA)
Hull York Medical School (GB)
University of British Columbia (CA)
University of Oslo (NO)
Utrecht University (NL)
ORCID: Bartoszko, Jessica J
Kum, Elena
Qasim, Anila
Zeraatkar, Dena
Izcovich, Ariel
Agoritsas, Thomas
Devji, Tahira
Ghadimi, Maryam
Honarmand, Kimia
McLeod, Shelley L
Rochwerg, Bram
Switzer, Charlotte
Vandvik, Per O
Vernooij, Robin WM
Wang, Ying
Yao, Liang
Guyatt, Gordon H
Venue: BMJ
Publisher: BMJ
Published: 2021-04-26
Volume: 373
Pages: n949
ISSN: 1756-1833 (ISSN-L)
DOI: 10.1136/bmj.n949
PMC: PMC8073806
OpenAlex: W3158131439
Cited by: 113
References: 84
Citations by year: 2026: 3 · 2025: 6 · 2024: 10 · 2023: 25 · 2022: 40 · 2021: 28
FWCI: 3.01
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
Locations: BMJ (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
cIRcle (University of British Columbia) (submittedVersion, cc-by-nc)
Lanzhou University Institutional Repository (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
MacSphere (McMaster University) (submittedVersion, cc-by-nc)
Funders: Canadian Allergy, Asthma and Immunology Foundation
American Academy of Allergy, Asthma and Immunology Foundation
Canadian Institutes of Health Research (174897_1, 174897)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords: COVID-19 prevention, COVID-19 pandemic, preventive medication, hydroxychloroquine, adverse drug reactions, hospitalization, mortality, drug discontinuation, quality of evidence, risk of bias assessment, GRADE, antiviral agents, antimalarial drugs
MeSH terms: COVID-19, SARS-CoV-2, Anti-Infective Agents, Carrageenan, Humans, Hydroxychloroquine, Ivermectin, Global Health, Treatment Outcome, Chemoprevention, Uncertainty

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prophylaxis against covid-19: living systematic review and network meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks